Summary: Left ventricular (LV) remodeling is a central process in the pathophysiology of heart failure (HF); however, the factors that influence remodeling patterns in individuals remain unclear. Clinical determinants (such as age, sex, blood pressure, and body size) only partially explain the interindividual variability of LV geometry in the population. We investigated the role of familial factors by studying a large, 2-generational community-based sample from the Framingham Heart Study, undergoing echocardiography in mid-to-late adulthood. We found strong evidence of concordance of LV geometry among related pairs of individuals within nuclear families (parentchild, sibling-sibling) but not among unrelated spousal pairs. The presence of a family member with abnormal LV geometry was associated with a 20% increased odds of altered LV geometric pattern in the offspring compared with the prevalence in our study population. Specifically, there were 40% increased odds of eccentric hypertrophy or concentric remodeling and almost 4-fold increased odds of concentric hypertrophy among family members of individuals with the corresponding abnormal LV geometric pattern. These associations remained significant after accounting for clinical factors known to influence LV geometry. Further, there was an association between parental heart failure and prevalence of eccentric LV geometry in their offspring. These data demonstrate a potential contribution of familial predisposition to patterns of LV remodeling and suggest that familial factors may play a role in adverse LV remodeling and heart failure progression in the community.
Conclusions: Our investigation of a 2-generational community-based sample demonstrates familial aggregation of LV geometry, with the greatest recurrence risk for concentric LV geometry, and establishes an association between eccentric LV geometry and parental HF. 1
Association of Genome-Wide Variation With the Risk of Incident Heart Failure in Adults of European and African Ancestry: A Prospective Meta-Analysis From the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium
Summary: Genetic factors contribute to heart failure (HF) onset and, to date, most approaches to identify genetic variants associated with HF risk have relied on candidate genes. No large-scale genome-wide investigation of HF risk has been published. We investigated the association of Ϸ2.5 million single-nucleotide polymorphisms (SNPs) with incident HF by meta-analyzing data from 4 communitybased prospective cohorts: the Atherosclerosis Risk in Communities Study, the Cardiovascular Health Study, the Framingham Heart Study, and the Rotterdam Study. Among 20 926 European-ancestry participants with 2526 incident HF events, we identified 1 locus with an SNP, whose P value (1.4ϫ10 Ϫ8 ) exceeded the genome-wide statistical significance threshold of 5ϫ10 7 and was associated with a 53% increase in HF risk. Among 2895 African-ancestry participants who had 466 incident events, we identified 1 locus with an SNP, whose probability value (6.7ϫ10 Ϫ8 ) exceeded the genome-wide statistical significance and was associated with a 46% increase in HF risk. We identified an additional 14 loci in European-and Africanancestry participants that were marked by high-signal SNPs with a P value Ͻ1.0ϫ10 5 . For most loci, risk estimates were modest and did not seem to differ in subjects without a myocardial infarction preceding HF onset. Our results suggest that there may be several genomic regions associated with new-onset HF in older adults and support the hypothesis that common genetic variation, regardless of the clinical mechanism responsible for reduced cardiac output in HF, contributes to the risk. These findings merit replication in other community-based settings of incident HF.
Conclusions:
We identified 2 loci that were associated with incident HF and exceeded genome-wide significance. The findings merit replication in other community-based settings of incident HF. 2
Serial Measurement of Growth-Differentiation Factor-15 in Heart Failure: Relation to Disease Severity and Prognosis in the Valsartan Heart Failure Trial
Summary: There is a growing interest in using biomarkers to obtain pathophysiological insight into and, possibly, to improve the management of patients with heart failure (HF). Considering that HF is a systemic disease, biomarkers reflecting cardiac and systemic abnormalities may add incremental information to cardiac-specific markers such as B-type natriuretic peptide and high-sensitivity troponin T. Growth-differentiation factor-15 (GDF-15) is a distant member of the transforming growth factor-␤ cytokine superfamily that is produced in the heart and vasculature in response to tissue injury and inflammation. Accumulating evidence indicates that the circulating levels of GDF-15 are associated with prognosis in patients with coronary artery disease. In the present sub-investigation from the Valsartan Heart Failure Trial (Val-HeFT), 85% of the patients with advanced, stable, chronic HF had elevated circulating levels of GDF-15. GDF-15 levels further increased during the course of 12 months in both the placebo and valsartan arms of the trial. Increases in GDF-15 were independently associated with the risks of future mortality and first morbid event after adjustment for clinical prognostic variables, B-type natriuretic peptide, and high-sensitivity troponin T and their 12-month changes. Changes in GDF-15 over time may therefore reflect a pathophysiological process that is related to the prognosis of HF and is not completely addressed by the therapies prescribed to the patients in Val-HeFT. Continued research should focus on the potential clinical application of GDF-15 as a biomarker in HF and an improved understanding of its pathophysiology that may reveal new treatment targets in HF.
Conclusions: GDF-15 reflects information from several pathological pathways and provides independent prognostic information in heart failure. GDF-15 levels increase over time, suggesting that GDF-15 reflects a pathophysiological axis that is not completely addressed by the therapies prescribed in Val-HeFT. 3 
Genomic Variation Associated With Mortality Among Adults of European and African Ancestry With Heart Failure: The Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium
Summary: This study investigated 2526 incident heart failure (HF) cases of European ancestry and 466 incident HF cases of African ancestry for an association between genome-wide variation and all-cause mortality. One variant in the CKLF-like MARVEL transmembrane domain containing 7 (CMTM7) genes was significantly associated with all-cause mortality in individuals of European ancestry with HF. CMTM7 is 1 of several chemokine-like factor genes clustered in the same region on chromosome 3p22. These results suggest that chemokines may play a role in survival of patients with HF. No genomic variation was significantly associated with mortality in individuals with HF of African ancestry. Future studies of this type may identify genes that lead to an improved understanding of HF pathophysiology and treatment of the disease. These findings warrant additional investigation, including replication, in other studies of HF.
Conclusions:
This study identified a novel locus associated with all-cause mortality among individuals of European ancestry with HF. This finding warrants additional investigation, including replication, in other studies of HF. 4
Heart Failure-Associated Changes in RNA Splicing of Sarcomere Genes
Summary: Changes in gene expression accompany and contribute to heart failure (HF). These gene expression changes have been documented at the whole-gene level using microarray-based, genome-wide expression profiling approaches; however, global changes in mRNA splicing in HF have not been previously studied. Here, we use a microarray that individually measures expression of each known or putative exon and reverse transcription polymerase chain reaction assays to examine splicing changes that accompany HF. We found that broad changes in mRNA splicing occur in the failing heart. Many of these changes were indicative of decreased efficiency of mRNA splicing, and, among the affected genes, there were several sarcomere genes. These splicing changes also were observed in hypertrophied myocardium with preserved systolic function, suggesting that the splicing changes may occur before the onset of overt HF. The splicing changes were characteristic of diseased myocardium. A prediction model using the splicing of 3 sarcomere genes discriminated failing from nonfailing hearts with 98% accuracy, providing proof of principle that splicing-based biomarkers may provide diagnostic and prognostic information on patients with heart disease. Future studies will be needed to prospec-tively evaluate the value of splicing-based myocardial biomarkers in individualizing therapy in HF. Future work also will be needed to determine whether changes in RNA splicing are functionally important in the pathogenesis of heart disease and whether targeted modulation of splicing is a useful therapeutic strategy for HF.
Conclusions:
Our data indicate that mRNA splicing is broadly altered in human heart disease and that patterns of aberrant RNA splicing accurately assign samples to control or disease classes. 5
Reciprocal Transcriptional Regulation of Metabolic and Signaling Pathways Correlates With Disease Severity in Heart Failure
Summary: Congestive heart failure (HF) is a leading cause of morbidity and mortality worldwide. Despite phenotypic similarities characterized by ventricular dilatation and reduced contractility, the extent of common and divergent gene expression between different forms of HF remains a matter of intense debate. Focusing on molecular pathways, we demonstrate that myocardial gene expression in 28 experimental models of nonischemic (pressure overload, tachypacing, chronic isoproterenol infusion, Chagas disease, and transgenic HF models) and ischemic HF is consistently characterized by downregulation of major metabolic pathways and concomitant upregulation of cell signaling pathways, thus recapitulating a fetal gene expression program. In contrast to this uniform transcriptional response observed in animal models, human HF microarray studies displayed a greater variability, with some studies even showing a reversed pattern. The reasons for this divergence are almost certainly multifactorial and include the lack of true nonfailing human control tissue (significant cardiac disease in nonfailing samples and differences in tissue preservation techniques, leading to a fetal gene expression pattern) and the effect of medication, namely angiotensin-converting enzyme (ACE) inhibitors and ␤-blockers, partially reversing the fetal gene expression pattern in failing samples. These results highlight the difficulties of interpreting results from real world human clinical samples and stress the importance of wellcontrolled animal models to elucidate disease mechanisms. We conclude that, irrespective of the etiology of HF, gene expression in failing myocardium is characterized by downregulation of metabolic transcripts and concomitant upregulation of cell signaling pathways, thus providing a unifying concept for the heterogeneous transcriptional response observed in phenotypically similar models of HF.
Conclusions: Irrespective of the etiology, gene expression in failing myocardium is characterized by downregulation of metabolic transcripts and concomitant upregulation of cell signaling pathways. Gene expression changes along this metabolic-signaling axis in mammalian myocardium are a consistent feature in the heterogeneous transcriptional response observed in phenotypically similar models of HF. 6
Puma Deletion Delays Cardiac Dysfunction in Murine Heart Failure Models Through Attenuation of Apoptosis
Summary: Puma (p53-upregulated modulator of apoptosis) is a tumor suppressor gene that exerts its effect through transcriptional activation. Puma and mdm4 represent 2 critical p53 targets; although puma serves as the major downstream proapoptotic effector of p53, mdm4 inhibits p53-mediated apoptosis by direct binding. Puma is a unique member of the Bcl-2 family because it integrates and implements most signals mediated by different apoptosis inducers. In the present study, we used puma knockout mice in 2 heart failure (HF) models, triggered by pressure overload and heart-specific mdm4-ablation, and found that puma-induced apoptosis may play a role in the progression of HF. Interestingly, Puma can be activated not only by pressure overload but also by myocardial ischemia. Our results thus provide insight into the function of the mdm4-p53-puma axis in cardiomyocytes, which could ultimately aid in the develop-ment of antiapoptotic drug candidates to treat various cardiac diseases. Moreover, lack of puma does not recapitulate the tumorprone phenotype observed in p53-negative mice. Because the mdm4-p53-puma interface has also been the focus of recent drug discovery efforts in cancer, additional functional analysis of this system in the heart could contribute to the development of safer anticancer therapies with minimal cardiotoxic side effects. Of note, puma is not the only contributor to cardiac signaling during HF, and further studies are required to elucidate its connection with other apoptotic pathways. In conclusion, puma antagonists might be developed in the future to provide cardiac protection without increasing susceptibility to tumors, an adverse effect of therapies based on p53 inactivation.
Conclusions:
Our data indicate that puma might be a critical component of the apoptotic signaling pathways that contribute to ventricular remodeling and HF. Therefore, puma inactivation may serve as a preferential target to prevent HF induced by cellular stress. 7
Cardiac Troponin T Measured by a Highly Sensitive Assay Predicts Coronary Heart Disease, Heart Failure, and Mortality in the Atherosclerosis Risk in Communities Study
Summary: Cardiac troponin T (cTnT) and troponin I are the biomarkers of choice in the evaluation of patients with acute coronary syndromes. Cardiac troponin has been independently associated with adverse outcomes after acute coronary syndrome, in patients with chronic heart failure (HF), and in the general population, although cTnT levels are detectable in only a small fraction of the general population with the use of current assays. A precommercial highly sensitive cTnT assay can detect 10-fold lower concentrations than currently available assays. We sought to define the prevalence of measurable cTnT using this new highly sensitive assay and the associations of cTnT levels with adverse cardiovascular events in participants in the Atherosclerosis Risk in Communities (ARIC) Study, aged 54 to 74 years, who were initially free of cardiovascular disease. We found that the new highly sensitive cTnT assay detected circulating cTnT in 66.5% of the ARIC sample (Ͻ1% would have been detected by the currently available cTnT assays) and that measured cTnT had strong associations with coronary heart disease (CHD) events, mortality, and HF and improved risk prediction. Cardiac troponin T appears to be an important marker of coronary heart disease, mortality, and HF risk even in a healthy middle-aged population without manifest cardiovascular disease.
Conclusions: Cardiac troponin T detectable with a highly sensitive assay was associated with incident CHD, mortality, and HF in individuals from a general population without known CHD/stroke. 8
Common Variants in HSPB7 and FRMD4B Associated With Advanced Heart Failure
Summary: Heart failure (HF) is a common, heterogeneous disorder that leads to substantial morbidity and mortality in the developed world. Although population-based studies have demonstrated a genetic component to common forms of HF, specific risk loci have been difficult to identify. In this study, we tested the broad hypothesis that common genetic variation in Ϸ2000 candidate genes of known importance to cardiovascular biology contribute to HF risk. We found that common single-nucleotide polymorphisms (SNPs) in HSPB7 (rs1738943) and FRMD4B (rs6787362) were associated with advanced HF in 2 white referral populations but not in blacks. For both SNPs, the minor allele was less frequent in cases than in controls, indicating that patients who carry the minor allele are at lower risk for HF, though the magnitude of these changes in risk are too small to be applied clinically. Thus, our findings identify HSPB7 and FRMD4B as novel HF susceptibility loci and should stimulate efforts to identify the underlying mechanisms.
Conclusions: Our findings identify regions containing HSPB7 and FRMD4B as novel susceptibility loci for advanced HF. More broadly, in an era of genome-wide association studies, we demonstrate how knowledge of candidate genes can be leveraged as a complementary strategy to discern the genetics of complex disorders. 9
Conditional Transgenic Expression of Fibroblast Growth Factor 9 in the Adult Mouse Heart Reduces Heart Failure Mortality After Myocardial Infarction
Summary: Paracrine mechanisms are thought to contribute to the beneficial effects of bone marrow cells on perfusion and function of the infarcted heart that have been demonstrated in experimental studies and some clinical trials. We have previously identified fibroblast growth factor 9 (FGF9) as 1 of Ͼ100 paracrine factors that are secreted from bone marrow cells after myocardial infarction (MI). In the embryonic heart, FGF9 is expressed by the epicardium and endocardium and provides an epithelial-to-mesenchymal signal to stimulate coronary artery formation and cardiomyoblast expansion in the developing myocardium. FGF9, however, is expressed only at very low levels in the adult heart. Using a tetracycline-responsive binary transgene system based on the ␣-myosin heavy chain promoter, we show here that conditional expression of FGF9 in the adult mouse myocardium supports functional adaptation and survival after MI. Transgenic FGF9 stimulated left ventricular hypertrophy with microvessel expansion, reduced interstitial fibrosis, attenuated fetal gene expression, preserved diastolic but improved systolic function, and markedly reduced heart failure (HF) mortality. A single injection of an adenoviral vector encoding FGF9 promoted similar improvements in left ventricular systolic function and survival after MI. Mechanistically, FGF9 acted primarily on endothelial cells to promote angiogenesis and paracrine release of prohypertrophic factors, including bone morphogenetic protein 6. These observations support the idea that secretome analyses in bone marrow cells can lead to the identification of secreted factors with therapeutic activity after MI. Specifically, the data suggest a previously unrecognized therapeutic potential for FGF9 after MI.
Conclusions: Conditional expression of FGF9 promotes myocardial vascularization and hypertrophy with enhanced systolic function and reduced HF mortality after MI. These observations suggest a previously unrecognized therapeutic potential for FGF9 after MI. 10
Genetic Deletion of Myostatin From the Heart Prevents Skeletal Muscle Atrophy in Heart Failure
Summary: The prevalence of chronic heart failure (HF) is steadily increasing in our population. Individuals with this disease face high rates of mortality (which were reported to be as high as 50% in 5 years) and dire symptoms such as dyspnea, edema, exercise intolerance, and muscle loss. Skeletal muscle atrophy occurs in up to 68% of patients with HF and has been identified as a strong independent risk factor for mortality. Despite these facts, the cause of muscle wasting in HF is unclear, and a targeted treatment option is lacking. In this study, we show that the mouse heart, when exposed to pathological hemodynamic burden consistent with HF, releases the protein myostatin, a well-known inhibitor of skeletal muscle growth, into the systemic circulation. Genetic ablation of myostatin specifically in the heart prevented skeletal muscle atrophy when HF was induced. Antithetically, genetically modified mice with enhanced myostatin expression in the myocardium showed skeletal muscle rarefaction, indicating that cardiac myostatin is sufficient to induce skeletal muscle wasting. Therapeutically, injection of a myostatinblocking antibody in mice with preexisting HF preserved muscle mass. Thus, myostatin inhibition might be a medically relevant avenue for the treatment of muscle wasting in HF.
Conclusions:
Myostatin released from cardiomyocytes induces skeletal muscle wasting in HF. Targeted inhibition of myostatin in cardiac cachexia might be a therapeutic option in the future. 11
Therapeutic Inhibition of miR-208a Improves Cardiac Function and Survival During Heart Failure
Summary: Chronic and acute stress to the heart results in a pathological remodeling response accompanied by cardiomyocyte hypertrophy, fibrosis, pump failure, myocyte degeneration, and apoptosis, which often culminate in heart failure (HF) and sudden death. Although classic pharmacological treatment strategies can reduce remodeling and prolong survival in patients with HF, these therapies are ultimately ineffective in preventing progression of the disease. Previously, we identified a microRNA, miR-208, encoded within an intron of the Myh6 gene that regulates the cardiac stress response. Although genetic deletion of miR-208 in mice failed to induce an overt phenotype at baseline, in response to several forms of cardiac stress, miR-208 -null mice showed virtually no cardiomyocyte hypertrophy or fibrosis and were unable to upregulate Myh7 expression. Data presented in this study show that delivery of a locked nucleic acid-modified antimiR against miR-208a in mice induces highly specific and sustained silencing of miR-208a in the heart without any observable side effects. Therapeutic silencing of miR-208a via subcutaneous delivery of antimiR-208a prevents pathological cardiac remodeling, functional deterioration, and lethality during heart disease. These beneficial effects correspond to significant changes in miRNAs within plasma. Our data show the potent beneficial effects of miR-208a inhibition, which could be very relevant for patients with HF. Because miR-208a is the sole cardiac-specific miRNA annotated so far, we believe that antimiR-208a might become a combination therapy with the current standard of care.
Conclusions:
These studies indicate the potential of oligonucleotidebased therapies for modulating cardiac miRNAs and validate miR-208 as a potent therapeutic target for the modulation of cardiac function and remodeling during heart disease progression. 12
The S1103Y Cardiac Sodium Channel Variant Is Associated With Implantable Cardioverter-Defibrillator Events in Blacks With Heart Failure and Reduced Ejection Fraction
Summary: Sudden cardiac death (SCD) risk stratification for primary prevention implantable cardioverter-defibrillators (ICDs) is currently limited to reduced ejection fraction, yet the majority of people having SCD do not meet these criteria, nor do the majority of patients receiving primary prevention ICDs derive benefit from the device. In this report, we show that the S1103Y variant in the cardiac sodium channel gene, present in approximately 13% of blacks, is associated with a 3-to 4-fold increase in ICD events in patients with reduced ejection fraction. This genetic association is independent of traditional clinical risk factors for SCD. Identifying patients with this variant may potentially improve risk stratification for SCD in blacks, in whom there is a high prevalence of this variant.
Conclusions: This is the first report that the S1103Y variant is associated with a higher incidence of ventricular arrhythmias in blacks with heart failure and reduced ejection fraction. 13
Multimarker Approach for the Prediction of Heart Failure Incidence in the Community
Summary: Several biological pathways have been individually implicated in left ventricular remodeling and/or heart failure (HF) development, but it is unclear whether biomarkers reflecting these pathways aid in the prediction and stratification of HF risk beyond standard risk factors. In a community-based sample, we prospectively related a panel of circulating biomarkers representing distinct biological pathways, viz, aldosterone-to-renin ratio (renin-angiotensin-aldosterone axis), C-reactive protein (inflammation), plasminogen activator inhibitor-1 (fibrinolysis), B-type natriuretic peptide (natriuretic peptide system), homocysteine (oxidative stress), and the urine albumin-to-creatinine ratio (endothelial function) to the risk of developing new-onset HF. We used a multimarker approach that permitted a comparison of the biomarkers in relation to their contributions to HF risk while limiting multiple testing. We also related a biomarker score (based on biomarkers associated with HF) to HF risk. After adjustment for conventional HF risk factors, B-type natriuretic peptide and urine albumin-to-creatinine ratio emerged as key HF risk predictors. When B-type natriuretic peptide and urine albumin-to-creatinine ratio were modeled as a biomarker score, we observed a striking 10-fold increase in HF incidence across tertiles of biomarker score. Biomarkers provided incremental information over clinical risk factors for predicting HF, as assessed by significant improvements in c statistic and net reclassification. The predictive ability of biomarkers was maintained in subgroups with normal left ventricular function, those with renal function, and those without intervening ischemic events. Our findings are consistent with the notion that activation of the natriuretic peptide system and the presence of endothelial dysfunction antedate and predict HF.
Conclusions: Using a multimarker strategy, we identified B-type natriuretic peptide and urinary albumin-to-creatinine ratio as key risk factors for new-onset HF with incremental predictive use over standard risk factors. 14
Role of RBM25/LUC7L3 in Abnormal Cardiac Sodium Channel Splicing Regulation in Human Heart Failure
Summary: We have previously shown that human heart failure (HF) is associated with abnormal mRNA splicing of the cardiac sodium channel. This abnormal mRNA splicing results in truncated sodium channels that are nonfunctional and a reduction in sodium channel current to levels known to cause sudden death. Here, we explored the mechanisms by which this abnormal splicing occurs. Using microarray comparisons of diseased and normal human hearts, we identified 2 splicing factors, RBM25 and LUC7L3, that were necessary and sufficient to cause the abnormal sodium channel splicing. These factors were upregulated by hypoxia and elevated angiotensin II, conditions known to be present in HF. Moreover, we showed that the responses of white cells and the heart to these 2 inciting stimuli were equivalent. The potential clinical implications of these findings include a possible mechanism whereby hypoxia is arrhythmogenic and blockade of the renin-angiotensin system is antiarrhythmic. Moreover, if white cell sodium channel splicing in vivo correlates with that in the myocardium, it may be possible to develop a blood test to assess sodium channel availability and arrhythmic proclivity. Finally, this work defines potential therapeutic targets to address arrhythmic risk in human HF.
Conclusions:
Of the 17 mRNA splicing factors upregulated in HF, RBM25 and LUC7L3 were sufficient to explain the increase in truncated forms and the reduction in full-length Na ϩ channel transcript. Because the reduction in channels was in the range known to be associated with sudden death, interruption of this abnormal mRNA processing may reduce arrhythmic risk in HF. 15
Familial Evaluation in Arrhythmogenic Right Ventricular Cardiomyopathy: Impact of Genetics and Revised Task Force Criteria
Summary: Arrhythmogenic right ventricular cardiomyopathy is a genetically determined autosomal dominant cardiac disorder caused by mutations in desmosomal genes. Clinical presentation is typically with arrhythmia and/or sudden death during the second and third decades. This study confirms this perspective: 51 of 100 probands presented with sudden death; 14 between the ages of 14 and 20 years.
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The study also examined family members in whom the molecular genetic status was known. Disease expression in relatives was milder, developed later in life, and was associated with a low incidence of arrhythmia/sudden death. Relatives with multiple genetic variants, however, had more severe disease expression with sudden death. It is unclear whether multiple variants explain the early presentation with sudden death seen in Ͼ30% of probands or whether later-onset disease is progressive, with clinical arrhythmia complications developing in later decades. The findings of this study underscore the role of mutation analysis with cascade screening of families to enable appropriate genetic counseling and targeted serial cardiac evaluation. The Importance of Genetic Counseling, DNA
Conclusions

Diagnostics, and Cardiological Family Screening in Left Ventricular Noncompaction Cardiomyopathy
Summary: In left ventricular noncompaction cardiomyopathy (LVNC), part of the LV wall is thickened and bilayered, consisting of a thick endocardial layer with prominent intertrabecular recesses and a thin, compact epicardial layer. To investigate the genetics of LVNC, we performed systematic family screening and extensive molecular testing of 58 consecutively diagnosed LVNC probands (49 adults and 9 children). This combined approach showed that 67% of LVNC is genetic in origin. In 64% of the probands, familial disease was demonstrated by screening 194 first-and second-degree relatives with electrocardiography and echocardiography. The majority (63%) of the relatives diagnosed with LVNC was asymptomatic, including 9 relatives with a mutation. Presymptomatic DNA testing also identified 8 unaffected (without the cardiac phenotype) carriers, explaining why many probands were initially unaware of familial disease. The molecular screening for mutations in 17 genes identified mutations in 11 genes in 41% of the probands (17 adults and 6 children). Most mutations were transmitted in an autosomal dominant mode. Two adults and 2 children were compound-or doubleheterozygous for 2 different mutations. One adult proband had 3 mutations. In half of familial LVNC, the genetic defect remained inconclusive. These results show that LVNC is predominantly a genetic cardiomyopathy, with variable clinical presentation ranging from asymptomatic to severe manifestations. Accordingly, the diagnosis of LVNC requires genetic counseling, DNA diagnostics, and echocardiographic family screening.
Conclusions: LVNC is predominantly a genetic cardiomyopathy, with variable presentation ranging from asymptomatic to severe. Accordingly, the diagnosis of LVNC requires genetic counseling, DNA diagnostics, and cardiological family screening. 17
Rare Variant Mutations in Pregnancy-Associated or Peripartum Cardiomyopathy
Summary: The term peripartum cardiomyopathy (PPCM) describes dilated cardiomyopathy (DCM) without known cause that occurs during the last month of pregnancy to 5 months postpartum. A related term, pregnancy-associated cardiomyopathy (PACM), refers to DCM onset earlier in pregnancy. Despite multiple studies focused on inflammatory, immunologic, and environmental causes, no unifying hypothesis has been proven. An alternative hypothesis is that PPCM and PACM result from a genetic cause. In an effort to identify preliminary support for this hypothesis, a systematic search of a large database, collected for family-based genetic dilated cardiomyopathy (DCM) studies over the past 15 years, was undertaken for cases associated with pregnancy and the postpartum period. When cases were identified, available clinical and molecular genetic data were analyzed. Of the 4110 women from 520 pedigrees in the Familial Dilated Cardiomyopathy Research Project database, 45 cases of PPCM/PACM were identified, 23 with familial clustering, of which 19 had been resequenced for known DCM genes. Six of these 19 carried mutations in genes shown previously to be associated with DCM. These data indicate that PPCM/PACM may have a genetic basis in some cases. Thus, we recommend that clinicians caring for patients with PPCM/PACM be aware that PPCM/PACM may have a genetic basis and that guidelines for evaluation of genetic cardiomyopathy be followed. Specifically, this includes clinical screening (family history, medical history, examination, ECG, echocardiography) of the patient and her first-degree relatives. Genetic counseling, including reproductive risk counseling about PPCM/PACM, is recommended, in addition to consideration of genetic testing.
Conclusions: These findings suggest that a proportion of PPCM/ PACM cases results from a genetic cause. 18
Genetic Variation in Titin in Arrhythmogenic Right Ventricular Cardiomyopathy-Overlap Syndromes
Summary: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a serious inherited myocardial disease characterized by fibrofatty replacement of the myocardium and a predisposition to cardiac arrhythmias and sudden death. Although genetic mutations affecting a number of protein components of intercalated disks, providing structural and electric connections between contracting myocytes, have been implicated in ARVC in the majority of cases, the underlying genetic defect is unknown. In this study, we evaluated the giant muscle protein titin as a candidate ARVC gene because of the known functional link between titin and elements of the intercalated disk and the prior finding of an ARVC genetic locus mapping to the titin region on chromosome 2. Screening of all 312 cardiac titin gene exons detected several variants, including 1 variant (Thr2896Ile) that showed strong genetic segregation evidence for being pathogenic. In vitro studies of the Thr2896Ile mutation support that structural impairment of the titin spring is a likely cause of ARVC and that this constitutes a novel mechanism underlying myocardial remodeling and sudden cardiac death.
Conclusions:
Our data provide evidence that titin mutations can cause ARVC, a finding that further expands the origin of the disease beyond desmosomal proteins. Structural impairment of the titin spring is a likely cause of ARVC and constitutes a novel mechanism underlying myocardial remodeling and sudden cardiac death. 19
Mutational Heterogeneity, Modifier Genes, and Environmental Influences Contribute to Phenotypic Diversity of Arrhythmogenic Cardiomyopathy
Summary: The diagnosis and risk stratification of arrhythmogenic cardiomyopathy are complicated by its broad clinical spectrum. Affected individuals have varying combinations of familial, ECG, arrhythmic, structural, and histological abnormalities, necessitating consensus guidelines to standardize diagnosis. Three subtypes are now recognized: left-dominant, biventricular, and the classic rightdominant form better known as arrhythmogenic right ventricular cardiomyopathy/dysplasia. Although substantial genetic and allelic heterogeneity may account for some of the clinical diversity, it cannot explain the observed disparities between members of the same family, all of whom carry the same mutation. Variation in other genes and/or in environmental factors must modify expression of the primary mutation. We used statistical models to estimate the relative contribution of mutational heterogeneity, genetic modifiers, and environmental influences to disease-associated traits, including right and left ventricular volumes, ejection fractions, and ventricular arrhythmia grade. Modifier genes appeared to contribute significantly to 6 of 9 traits examined, whereas mutational heterogeneity and environment were dominant influences for the remainder.
Systematic investigation of modifier genes and environmental influences in arrhythmogenic cardiomyopathy will facilitate refinement of diagnostic and prognostic algorithms, formulation of evidencebased lifestyle guidelines, and identification of novel therapeutic targets.
Conclusions: Systematic investigation of modifier genes and environmental influences will be pivotal to understanding clinical diversity in arrhythmogenic cardiomyopathy, refining prognostication, and developing targeted therapies. 20
Sarcomere Gene Mutations in Isolated Left Ventricular Noncompaction Cardiomyopathy Do Not Predict Clinical Phenotype
Summary: Left ventricular noncompaction of the myocardium (LVNC) is a cardiomyopathy with a genetic etiology, and autosomaldominant transmission is common. The morphological echocardiographic characteristics include a severely thickened, 2-layered myocardium, numerous prominent trabeculations, and deep intertrabecular recesses. The clinical features range from asymptomatic individuals to patients with symptoms, with progressive deterioration of cardiac function; thromboembolic events; and arrhythmias, including sudden cardiac death. LVNC is genetically heterogeneous, and prior reports indicate that mutations in genes encoding sarcomere proteins are associated with LVNC. In the present study, we evaluated the potential clinical impact of genetic analysis of sarcomere genes in patients with isolated LVNC. We describe mutations in cardiac myosin-binding protein C (MYBPC3) and ␣-tropomyosin (TPM1) in a cohort of unrelated adult probands with isolated LVNC. The mutations in MYBPC3 and TPM1 and in 6 other previously reported sarcomere genes in this cohort resulted in a total of 18 (29%) heterozygous mutations in 63 probands. Betamyosin heavy chain (MYH7) was the most prevalent disease gene, accounting for 13% of cases, followed by MYBPC3 (8%). Although mutations in sarcomere genes account for a significant proportion of cases of isolated LVNC, patients who are mutation-positive could not be distinguished from those who are mutation-negative by their clinical characteristics; however, we provide insight into how mutations of different sarcomere genes lead to diverse clinical phenotypes, with implications for diagnosis, genetic testing, and follow-up. Genetic testing of sarcomere genes is a valuable diagnostic tool for the probands and their relatives who may be at high risk of inheriting the cardiomyopathy.
Conclusions:
Mutations in sarcomere genes account for a significant (29%) proportion of cases of isolated LVNC in this cohort. The distribution of disease genes confirms genetic heterogeneity and opens new perspectives in genetic testing in patients with LVNC and their relatives at high risk of inheriting the cardiomyopathy. The presence or absence of a sarcomere gene mutation in LVNC cannot be related to the clinical phenotype. 21
Prevalence of Desmosomal Protein Gene Mutations in Patients With Dilated Cardiomyopathy
Summary: Idiopathic dilated cardiomyopathy (DCM) is defined by the presence of a dilated and poorly functioning left ventricle in the absence of abnormal loading conditions or ischemic heart disease sufficient to cause global systolic impairment. A large number of cardiac and systemic diseases can result in systolic impairment and left ventricular dilatation, but, in the majority of patients, no identifiable cause is found. At least 25% of adult patients with DCM have evidence for familial disease, and 20% of adult relatives of these probands have isolated left ventricular enlargement that can progress to DCM. Numerous genetic mutations are linked with DCM in association with skeletal, neurological, and other extracardiac abnormalities, but the genetic basis in most cases of isolated DCM remains elusive. This study shows that a proportion of patients with typical DCM harbor mutations in genes that encode proteins of the intercalated discs (the end-to-end connections between cardiomyo-cytes responsible for maintenance of mechanical and electric integrity). Before this study, mutations in these genes were thought to be synonymous with another disease, arrhythmogenic right ventricular cardiomyopathy (ARVC), but the demonstration that ARVC and DCM share a common molecular basis indicates that these disorders may simply be different facets of the same underlying pathological process.
Conclusions: Heart failure caused by a dilated, poorly contracting left ventricle and ARVC have been considered distinct clinicopathologic entities. This study suggests that both clinical presentations can be caused by mutations in desmosomal protein genes. 22
Homozygosity Mapping and Exome Sequencing Reveal GATAD1 Mutation in Autosomal Recessive Dilated Cardiomyopathy
Summary: Recognition of idiopathic dilated cardiomyopathy (DCM) as a heritable disorder in 25% to 50% of patients with this condition has provided a rationale for screening echocardiography in at-risk relatives to detect presymptomatic disease. Furthermore, familial DCM has been the impetus for human genetics investigations to uncover the molecular underpinnings of myopathic heart failure (HF). DCM is now well-established as a genetically heterogeneous disorder, yet mutations in identified genes are estimated to account for only one third of cases. Beyond targeted hypothesis-based screening of candidate genes, completion of the Human Genome Project and technological advances in DNA analysis have enabled powerful whole-genome approaches that overcome inherent limitations of traditional disease gene discovery. These approaches can, in fact, uncover unanticipated DCM genes and new insights into the pathobiology of HF. In this study, we identified and phenotypically characterized a consanguineous family with nonsyndromic DCM segregating as an autosomal recessive trait. Exome sequencing, providing comprehensive sequence data for protein-coding regions of virtually all genes, and genome-wide locus mapping, providing a positional filter for the large number of identified genetic variants, were used as synergistic strategies to identify a pathogenic homozygous mutation in GATAD1. Previous work has shown that GATAD1 binds to histones, the fundamental building blocks of chromatin that package and condense DNA and serve as targets for posttranslational modification and regulation of gene expression. Consistent with murine DCM caused by genetic disruption of histone deacetylases, the data implicate an inherited basis for epigenetic perturbation as an underlying basis for human HF.
Conclusions: Linkage analysis and exome sequencing were used as synergistic genomic strategies to identify GATAD1 as a gene for autosomal-recessive DCM. GATAD1 binds to a histone modification site that regulates gene expression. Consistent with murine DCM caused by genetic disruption of histone deacetylases, the data implicate an inherited basis for epigenetic dysregulation in human HF. 23
Sarcomere Protein Gene Mutations in Patients With Apical Hypertrophic Cardiomyopathy
Summary: This study describes genetic findings in a patient cohort with apical hypertrophic cardiomyopathy (HCM) who underwent genetic testing for clinical purposes. We compared the frequency and distribution of sarcomere protein gene mutations of those of our cohort of patients with apical HCM with those with nonapical HCM. Importantly, fewer patients with apical HCM (13%) had a diseasecausing mutation compared with 40% in the nonapical HCM cohort. There was no unique gene identified that was specific for apical HCM. Thus, family screening in patients with apical HCM can only be simplified in a relatively small number of affected families by screening for the disease-causing mutation of the index patient within the family members. Hence, conventional clinical screening, including ECG and echocardiography over regular intervals, remains crucial. The low prevalence of mutations found in patients with those e20 Circ Cardiovasc Genet June 2012 of our cohort of HCM patients with nonapical HCM. Importantly, fewer patients with apical HCM (13%) had a disease-causing mutation compared with 40% in the nonapical HCM cohort. There was no unique gene identified that was specific for apical HCM. Thus, family screening in patients with apical HCM can only be simplified in a relatively small number of affected families by screening for the disease-causing mutation of the index patient within the family members. Hence, conventional clinical screening including ECG and echocardiography over regular intervals remains crucial. The low prevalence of mutations found in patients with apical HCM indicates the need for further genetic studies to detect abnormalities at sites not currently tested for.
Conclusions:
In apical HCM, a positive genotype was found less frequently than in nonapical HCM, and it was most often involving MYBPC3 and MYH7genes. Only 13% of patients with apical HCM were found to be genotype-positive, indicating that genome-wide association studies and gene expression profiling are needed for better understanding of the genetic background of the disease. There was no significant genotype-phenotype correlation in our cohort with apical HCM. 24
Peripartum Cardiomyopathy as a Part of Familial Dilated Cardiomyopathy
Summary: Anecdotal cases with familial clustering of peripartum cardiomyopathy (PPCM) or joint occurrence of PPCM and idiopathic dilated cardiomyopathy (DCM) within families have been reported. We performed the first systematic study of the relation between PPCM and familial DCM. In a substantial number of DCM families (5/90), cases of PPCM were found, and, more importantly, previously undiagnosed cases of DCM were identified in all 3 families of patients with PPCM who did not show a full recovery. Moreover, our results support the genetic nature of the disease in 1 DCM family with PPCM: We identified a mutation in the gene encoding cardiac troponin C (TNNC1). We therefore conclude that PPCM can be a manifestation of familial DCM. Obviously, further research is needed to confirm these observations in a larger series of patients; however, our findings already have several clinical implications and may change clinical practice and thinking about PPCM. Because PPCM can be the first manifestation of familial DCM, we recommend presymptomatic cardiological screening for covert DCM in first-degree family members of patients with PPCM without recovery of left ventricular function and dimensions. Second, cardiological screening during pregnancy should be considered for healthy women (ie, without proven previous signs of DCM) who are first-degree family members of patients with familial DCM and this should be extended into the puerperium.
Conclusions: Our findings strongly suggest that a subset of PPCM is an initial manifestation of familial DCM. This may have important implications for cardiological screening in such families. 25
Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: Pathogenic Desmosome Mutations in Index-Patients Predict Outcome of Family Screening: Dutch Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Genotype-Phenotype Follow-Up Study
Summary: Arrhythmogenic right ventricular dysplasia (ARVD)/cardiomyopathy (C) usually shows an autosomal dominant inheritance pattern, with incomplete penetrance and variable clinical expression. Classically, index patients present between the second and fourth decades of life with right ventricular tachycardia; however, sudden death can occur at adolescence, whereas mutation carriers may remain without signs and symptoms until old age. Previous genotype-phenotype studies involved mainly overt index patients. Data on mainly asymptomatic relatives were scarce. To gain insight into the full spectrum of the disease, 149 index patients with ARVD/C and 302 of their relatives were genotypically and phenotypically characterized. DNA analysis comprised sequencing of the desmosomal genes PKP2, DSC2, DSG2, DSP, and JUP and multiplex ligation-dependent probe amplification to identify large deletions in PKP2. Pathogenic mutations were identified in 87 of 149 index patients with ARVD/C (58%), mainly truncating PKP2 mutations with multiple mutations in 2% of cases. Performing multiplex ligation-dependent probe amplification also appeared to be important; its 2% mutational yield was comparable with the sequencing of DSG2 or DSC2. Identification of mutations in index patients had major consequences for the concurrent relatives. Of the 57 of 282 initially asymptomatic relatives (20%) who showed any sign of ARVD/C, 84% carried a mutation. These 48 mutation carriers had earlier onset of disease signs and symptoms than noncarriers but also a markedly increased risk of arrhythmias and 6-fold risk of ARVD/C diagnosis. Familial cases were identified in 45% of families screened. Prolonged terminal activation duration seemed to be an early marker of ARVD/C; it was observed more often than negative T waves in V1 to V3, especially in mutation-carrying relatives Ͻ20 years of age.
Conclusions: Pathogenic desmosomal gene mutations, mainly truncating PKP2 mutations, underlie ARVD/C in the majority (58%) of Dutch index patients and even 90% of familial cases. Additional multiplex ligation-dependent probe amplification analysis contributed to discovering pathogenic mutations underlying ARVD/C. Discovering pathogenic mutations in index patients enables those relatives who have a 6-fold increased risk of ARVD/C diagnosis to be identified. Prolonged terminal activation duration seems to be a first sign of ARVD/C in young asymptomatic relatives. 26
Molecular Genetic and Functional Characterization Implicate Muscle-Restricted Coiled-Coil Gene (MURC) as a Causal Gene for Familial Dilated Cardiomyopathy
Summary: Heart failure (HF) is a major cause of mortality and morbidity. Genetic mutations are important causes of susceptibility to HF. Familial dilated cardiomyopathy (DCM) is a classic form of systolic HF caused by genetic mutations. The known causal genes for DCM typically code for sarcomere and cytoskeletal proteins. Prompted by the experimental data, which implicate Muscle-Restricted Coiled-Coil (MURC) in regulating cardiac function, we investigated the causal role of the MURC gene in DCM. We sequenced the protein coding regions of MURC in 383 probands with DCM, 307 with hypertrophic cardiomyopathy, and 509 healthy control subjects. We found 6 missense mutations that were present only in patients with DCM and were absent in control subjects. Two of these mutations segregated with inheritance of DCM in small families. One mutation recurred in 3 independent probands, including 1 proband who also had another mutation in the ␣-tropomyosin gene. We also found 1 deletion mutation in 3 unrelated probands with hypertrophic cardiomyopathy that might be a causative or susceptibility variant. The clinical features associated with MURC mutations included progressive HF that often led to heart transplantation, conduction defects, and atrial arrhythmias. Studies in cultured cardiac myocytes showed that the mutations reduced RhoA activity, an important signal transducer in the heart and impaired myocyte hypertrophic response. We conclude that MURC probably is a causal gene for DCM. We suggest elucidation of the molecular genetic and pathogenesis of HF is an essential step in the ultimate treatment of this potentially deadly disease.
Conclusions: MURC mutations impart loss-of-function effects on MURC functions and probably are causal variants in human DCM. The causal role of a deletion mutation in HCM is uncertain. 27 The Editors Most Read on Heart Failure e21
Morphological Analysis of 13 LMNA Variants Identified in a Cohort of 324 Unrelated Patients With Idiopathic or Familial Dilated Cardiomyopathy
Summary: Dilated cardiomyopathy (DCM) is a remarkably heterogeneous genetic disease. From 20% to 50% of DCM cases may have an underlying genetic cause. Mutations in Ͼ30 genes have been associated with DCM but only explain an estimated 25% to 30% of overall familial cases. Mutations in LMNA, encoding lamin A/C, have been detected in 5% to 10% of families with DCM. That Ͼ30 genes are involved (locus heterogeneity) greatly complicates investigative strategies. Furthermore, almost all DCM mutations are private or specific to a family (allelic heterogeneity). This fact makes it necessary to sequence all coding exons of each gene to detect the variants relevant for disease, but even if a novel genetic variant is detected that changes the coding of an amino acid, the additional challenge is to verify that the variant truly is disease-causing. This study examined 13 of 18 LMNA variants detected in the DNAs from 324 DCM probands, the largest series reported to date. The aim of this study was to gain further evidence that the identified variants were indeed pathogenic, particularly those identified in families too small to assess segregation of the variant with disease, and variants associated with nonsegregation within pedigrees. After expression in a cell system, confocal microscopy-based studies of abnormal nuclear lamina architecture were conducted in cells expressing the LMNA variants. In most cases, the LMNA variants seemed to be disease-causing. This study illustrates the use and need for sensitive methods to determine the potential pathogenicity of genetic variants.
Conclusions: This work expands the recognized spectrum of lamin A localization abnormalities in dilated cardiomyopathy. It also provides evidence supporting pathogenicity of 10 of 13 tested LMNA variants, including some with uncertain or nonsegregation. 28
Coding Sequence Rare Variants Identified in MYBPC3, MYH6, TPM1, TNNC1, and TNNI3 From 312 Patients With Familial or Idiopathic Dilated Cardiomyopathy
Summary: Several studies have focused on discovering the genetic causes of dilated cardiomyopathy (DCM) that occurs in families (familial DCM). Mutations in Ͼ30 genes have now been shown to be associated with DCM. To extend our understanding of DCM genetics, we conducted resequencing studies (where the DNA samples from patients with DCM were sequenced for nucleotide variation in selected genes) in a large cohort of patients with familial DCM and in patients with apparently nonfamilial DCM of unknown cause (idiopathic DCM). In this study, 5 sarcomeric genes were resequenced in 312 DCM probands, 181 with familial DCM, and 131 with idiopathic DCM. Variants that were considered rare (ie, not present in 492 chromosomes from control subjects) and that changed highly conserved amino acids or affected intron/exon splicing were identified in 34 probands (10.9% overall). These variants were classified as likely disease-causing in 13 or possibly disease-causing in 20 probands and included 12 MYBPC3 (myosin-binding protein C) in 13 (4.2%) probands, 8 MYH6 (␣-myosin heavy chain) in 10 (3.2%), 6 TPM1 (tropomyosin) in 6 (1.9%), 4 TNNC1 (cardiac troponin C) in 4 (1.3%), and 1 TNNI3 (cardiac troponin I) in 2 (0.6%). A similar fraction of rare variants were identified in familial DCM and idiopathic DCM, suggesting that idiopathic DCM also may have a genetic basis. This investigation, when combined with previous resequencing studies of 9 genes, suggests that 27% of DCM probands have had a possibly or likely genetic cause identified.
Conclusions: Rare variants in these 5 genes likely or possibly caused 10.6% of DCM in this cohort. When combined with our prior resequencing reports, Ϸ27% of DCM probands had possible or likely disease-causing variants identified. 29
A ZASP Missense Mutation, S196L, Leads to Cytoskeletal and Electric Abnormalities in a Mouse Model of Cardiomyopathy
Summary: Dilated cardiomyopathies (DCMs) are often genetic and associated with arrhythmias and sudden cardiac death. The links between genetic mutations causing DCM and arrhythmias are not well-defined. We studied a mouse model for the S196L mutation in the cytoskeletal protein ZASP previously identified in a family with DCM and sudden cardiac death. Affected mice have evidence of electric abnormalities at 3 months of age and develop hemodynamic impairment and rhythm disturbances by 10 months of age. In isolated cells, the ZASP4-S196L mutation was found to affect L-type Ca 2ϩ currents and Na ϩ currents. Furthermore, ZASP can form a protein complex including both calcium (Ca v 1.2) and sodium (Na v 1.5) channels and the ZASP-binding partners Z-disk proteins ␣-actinin-2 and Telethonin. These findings suggest that primary mutations in any of the components of such complexes could lead to disturbances in the intertwined connection between the cytoskeleton and ion channels, suggesting a group of potentially novel causes of cardiomyopathies associated with arrhythmias.
Conclusions: Our findings provide new insight into the mechanisms by which mutations of a structural/cytoskeletal protein, such as ZASP, lead to cardiac functional and electric abnormalities. This work represents a novel framework to understand the development of conduction defects and arrhythmias in subjects with cardiomyopathies, including DCM. 30
Protein Aggregates and Novel Presenilin Gene Variants in Idiopathic Dilated Cardiomyopathy
Summary: Heart failure (HF) is a progressive and ultimately fatal disease, which represents a leading public health problem worldwide. Despite substantial advances in the clinical management of HF, the only current permanent therapeutic option is heart transplantation; however, the limited supply of functional organs for transplantation and the age threshold for the surgical intervention constrain the scope of this treatment modality. The majority of cases of HF are ischemic in origin. The second most frequent origin of nonischemic HF is idiopathic dilated cardiomyopathy (DCM), in which no other causative events can be recognized. Recent studies highlight the recognition of the public health importance of a large number of diseases associated with defects in the ability of proteins to fold, leading to the accumulation of cytotoxic protein deposits. This group of diseases includes amyloidosis and various neurodegenerative disorders such as Alzheimer disease. Preliminary evidence suggests that idiopathic dilated cardiomyopathy may be included among these misfolding diseases. In addition, mutations in the same genes causing Alzheimer disease in a significant percentage of cases can also be at the origin of idiopathic DCM. Interestingly, a dual mechanism seems to mediate the effect of these genetic variations: (1) changes in the control of Ca 2ϩ -handling proteins causing defect in the contractile function; and (2) cell damages associated with the protein aggregation process. The incidence, prognosis, and therapeutic options for idiopathic DCM may therefore be greatly advanced by establishing a fundamental understanding of key factors leading to the disease.
Conclusions: On the basis of these findings, we propose that 2 mechanisms may link protein aggregation and cardiac function: oligomer-induced changes on Ca 2ϩ handling and a direct effect of PSEN1 sequence variants on excitation-contraction coupling protein function. 31 terized by adherence of the septal and posterior leaflets of the tricuspid valve to the underlying myocardium. Ebstein anomaly is more common in patients with a family history of congenital heart disease, but most cases are sporadic, and familial Ebstein anomaly is rare. Associated abnormalities of left ventricular morphology and function have been observed. A possible association between Ebstein anomaly with left ventricular noncompaction (LVNC) and mutations in MYH7 encoding ␤-myosin heavy was previously shown in 1 family with multiple affected members. In the present study, we describe that Ebstein anomaly is within the diverse spectrum of cardiac morphologies triggered by a sarcomere gene defect. We performed mutational analysis of MYH7 in a cohort of 141 unrelated probands with Ebstein anomaly. Mutations were identified in 8 of 141 probands (6%), the largest resequencing study of Ebstein anomaly thus far. Mutation-positive probands and family members showed various congenital heart malformations, as well as LVNC. Significant pleiotropy and reduced penetrance were characteristic of MYH7 mutation-positive congenital heart malformations. In 6 of 8 probands with MYH7 mutations, LVNC was identified in addition to Ebstein anomaly, whereas among 133 MYH7 mutation-negative probands, none had LVNC. We provide further evidence for a link between structural proteins, cardiomyopathy, and congenital heart malformations. MYH7 mutations are predominantly found in Ebstein anomaly associated with LVNC and may warrant genetic testing and family evaluation in this subset of patients.
Conclusions: Ebstein anomaly is a congenital heart malformation that is associated with mutations in MYH7. MYH7 mutations are predominantly found in Ebstein anomaly associated with LVNC and may warrant genetic testing and family evaluation in this subset of patients. 32
Ca 2؉ /Calmodulin-Dependent Kinase II␦ Causes Heart Failure by Accumulation of p53 in Dilated Cardiomyopathy
Summary: Heart failure (HF) is an important cause of morbidity and mortality in many industrial countries, and dilated cardiomyopathy (DCM) is 1 of its major causes. Molecular genetic studies over the last 2 decades have revealed many mutations of various genes in patients with DCM, but the precise mechanisms of how such mutations lead to DCM remain largely unknown partly because of a lack of good animal models of DCM. Here, we established the mouse model of DCM by expressing a mutated cardiac ␣-actin gene, which has been reported in patients with DCM, in the heart. The transgenic mice showed gradual dilatation and dysfunction of the left ventricle, resulting in death by HF. These phenotypes of the transgenic mice were quite similar to those of human DCM. The number of apoptotic cardiomyocytes and protein levels of p53 were increased in the hearts of the DCM mice. Overexpression of Bcl-2, an antiapoptotic factor, or downregulation of p53 decreased the number of apoptotic cardiomyocytes and improved cardiac function. The DCM mice showed activation of CaMKII␦. The molecular mechanism leading to these microdeletions was owing to a novel Alu-mediated homologous unequal recombination or subsequent to chromosomal breakage mediated by interspersed TA-rich repetitive elements, which are among the mechanisms leading to genomic copy number variation. Our observation in 3 patients with Danon disease suggests that this mechanism may have been underestimated in select cardiovascular disorders. The X-linked nature of Danon disease allowed us to detect LAMP2 gene microdeletion in male patients through commonly used techniques such as polymerase chain reaction; however, if microdeletions occur in autosomal-dominant diseases, the standard mutational analysis may fail to detect the lack of 1 of the 2 wild-type alleles, thus leading to a false-negative mutational screening and an undetected copy number variation in these patients. Therefore, our findings suggest that copy number variation analysis in cardiomyopathies and generally in cardiovascular diseases represents an uncharted territory that must be comprehensively investigated in future studies.
Conclusions: This article is the first report of Danon disease caused by microdeletions at Xq24, which functionally ablate LAMP2. The microdeletion mechanism appears to involve 1 Alu-mediated unequal recombination and 2 chromosomal breakage points involving TA-rich repeat sequences. 34
Striking In Vivo Phenotype of a Disease-Associated Human SCN5A Mutation Producing Minimal Changes in Vitro
Summary: A conventional approach to characterize the function of ion channel mutations is to compare wild-type and variant channel function by heterologous expression in mammalian, noncardiac cells such as Chinese hamster ovary or human embryonic kidney cells. The cardiac sodium channel mutation D1275N has been reported in multiple individuals and families with a range of phenotypes, including arrhythmias and dilated cardiomyopathy (DCM); however, conventional heterologous expression studies have not identified major differences between wild-type and D1275N function. Thus, it has even been uncertain whether this mutation causes the clinical phenotypes with which it has been associated. In this study, we addressed this issue by studying mice in which the cardiac sodium channel locus had been disrupted and replaced with full-length human wild-type or D1275N mutant sodium channels. We observed slowed and disordered cardiac conduction and decreased contractile function in mice bearing the mutation; mice with 2 D1275N alleles displayed worse phenotypes than those with 1 variant allele. In vitro electrophysiological studies identified reduced peak cardiac sodium current as a key defect, and this is consistent with the observed reduced conduction velocity. The major clinical implication of these findings is that heterologous expression may be insufficient to assess mutant channel function. In addition, the data lend support to the concept that sodium channel mutations are associated not only with arrhythmias but also with DCM phenotypes. The mutant mice will be an invaluable tool to dissect mechanisms underlying these findings.
Conclusions: Although D1275N produces near-normal currents in multiple heterologous expression experiments, our data establish this variant as a pathological mutation that generates conduction slowing, arrhythmias, and a DCM phenotype by reducing cardiac sodium current. 35 The Editors Most Read on Heart Failure e23
A Comprehensive Genetic Study on Left Atrium Size in Caribbean Hispanics Identifies Potential Candidate Genes in 17p10
Summary: Left atrial (LA) enlargement is associated with increased mortality, ischemic stroke, atrial fibrillation, and other adverse cardiovascular outcomes. Although hemodynamic factors have long been considered the major determinants of atrial size, the emerging inherited contribution to atrial arrhythmias suggests that there may be underlying genetic determinants of atrial size also. Identifying genetics factors contributing to LA size may help identify individuals at risk of developing LA enlargement and perhaps its adverse sequel. In addition, understanding the genetic determinants may facilitate the identification of therapeutic targets for the management of LA enlargement. Using well-characterized, extended families and an independent sample from a community-based prospective cohort, we evaluated the genetic correlates of LA size. Our data demonstrate that genetic factors explain a moderate proportion of variance in LA size and indicate that several genes on chromosome 17p10 may influence LA size. Among the potential candidate genes identified, myocardin (MYOCD) has been shown to be a key transducer of hypertrophic signals in cardiomyocytes in vitro. Our study is consistent with the notion that genetic variations in MYOCD may modify LA size. Large-scale genetic studies and additional functional studies are warranted to further evaluate the contribution of genetic variants in the identified loci to interindividual variation in LA size.
Conclusions: Using nonbiased genome-wide linkage followed by peak-wide association analysis, we identified several possible susceptibility genes affecting LA size. Among them, MYOCD has been shown to serve as a key transducer of hypertrophic signals in cardiomyocytes. Our data support that polymorphisms in MYOCD modify LA size. 36
Transcriptomic Biomarkers for the Accurate Diagnosis of Myocarditis
Summary: New diagnostic tools based on gene signatures derived from the entire complement of messenger RNAs in a cell or tissue have become established in the clinical management of certain disorders, particularly cancer. The comprehensiveness of this approach contributes to its accuracy. Myocarditis is a disorder that causes a substantial proportion of patients presenting with new-onset heart failure and left ventricular dysfunction. Typically diagnosed by endomyocardial biopsy and evaluated with histological criteria called the Dallas criteria, clinical management is hampered by low sensitivity and specificity and the need for multiple cardiac biopsies. The present study suggests that the application of a transcriptomic based biomarker can substantially improve the diagnostic accuracy of heart biopsy for myocarditis. Using endomyocardial biopsy tissue obtained at the time of clinical presentation, we developed a molecular signature comprising 62 genes that predicted with high accuracy the presence of myocarditis in a population of 48 patients. Importantly, this required evaluation of tissue from a single endomyocardial biopsy sample and therefore is clinically practical. The present results could provide treating physicians with important and accurate diagnostic information about individual patients and could provide tools for personalized treatment or monitoring. Given emerging treatment strategies for viral and inflammatory myocarditis, accurate diagnostic tools are of increased importance.
Conclusions: Together, these findings demonstrate that transcriptomic biomarkers from a single endomyocardial biopsy can improve the clinical detection of patients with inflammatory diseases of the heart. This approach advances the clinical management and treatment of cardiac disorders with highly variable outcome. 37
Novel Nonmajor Histocompatibility Complex-Linked Loci From Mouse Chromosome 17 Confer Susceptibility to Viral-Mediated Chronic Autoimmune Myocarditis
Summary: The identification of susceptibility genes for virusinduced chronic myocarditis and dilated cardiomyopathy is an evolving field. Chromosome substitution strain mice are a unique and powerful resource that allows the investigator to quickly identify genetic determinants associated with select disease. Chromosome substitution strain mice contain 1 chromosome from the diseasesusceptible A/J strain on an otherwise resistant C57BL/6 background. Using these mice and mice congenic for smaller segments of chromosome 17, we identified 4 susceptibility loci on chromosome 17 for virus-induced autoimmune myocarditis. Two of these loci are novel with regard to the disease association and are located in the proximal portion of chromosome 17. These 2 loci encompass 35 and 69 possible susceptibility genes, respectively. A third locus encodes a number of genes associated with disease susceptibility, including the major histocompatibility complex locus. Characterization of the expression and function of these identified candidate genes within the disease-associated loci will allow us to determine the true susceptibility gene for virus-induced myocarditis and will facilitate the study of how disease risk is conferred. Identification of virusinduced myocarditis susceptibility genes will allow patients to be identified as susceptible to heart disease and to be more efficiently monitored for disease progression. With identification of early-onset patients, treatment could potentially be started at the initiation of disease and thereby limit the damage to the myocardium and arrest or slow disease progression to dilated cardiomyopathy. Further, better identification of patients with increased susceptibility to viral myocarditis could lead to the practical development and use of a vaccine to reduce the development of myocarditis later in life.
Conclusions:
We have identified 4 loci that confer susceptibility of viral-induced chronic myocarditis. Of these loci, 3 were distinct from the major histocompatibility complex locus and thus represent novel susceptibility loci. The close proximately of the 2 novel loci with susceptibility loci for other autoimmune diseases such as type 1 diabetes and chronic experimental autoimmune thyroiditis suggests the presence of global autoimmune susceptibility genes. 38
Distinct Epigenomic Features in End-Stage Failing Human Hearts
Summary: Molecular research in heart failure (HF) points to the hypothesis that a generic cardiac genomic response is activated in the failing myocardium regardless of the original inciting cause. This cardiac genomic stress response is typified by the reexpression of fetal genes, upregulation of fibrosis-related genes, and others. It may also reflect unifying features of a failed myocardium such as fibrosis, altered energy use, vascular rarefaction, cell death, and altered contractility, all of which are features found in the failing myocardium again regardless of the inciting cause. The epigenome refers to marks on the genome, including DNA methylation and histone modification. The epigenome regulates the expression of underlying genes, and recent evidence suggests that part of the epigenome may be altered by diet and the environment. In our research, we have examined the genome-wide landscape of the epigenome of healthy and end-stage cardiomyopathic human hearts. We have determined that distinct epigenomic patterns exist in important DNA elements of the human cardiac genome in the failing myocardium. Individually, sites of differential epigenomic patterns may control the expression of specific genes with critical functions in the progression of HF; however whether the altered epigenome is simply a consequence in end stage disease or actually contributes to disease progression remains to be determined. This work now opens an important new avenue of research because the epigenome may represent a drug discovery target for novel HF therapy.
